VISCO (6782) reported revenue of NT$527.8 million for Oct 2026, +60.0% year on year and +6.6% from the previous month. Revenue for Jan–Oct 2026 was NT$4.47 billion (+28.6% year on year).
Revenue for Oct 2026 was a record high (previous high: Sep 2026, NT$495.2 million). →
Year-on-year revenue growth: 6 months in a row. →
In Oct 2026, it ranked No. 16 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$527.8 million | +60.0% | +6.6% |
| Sep 2026 | NT$495.2 million | +14.9% | +1.1% |
| Aug 2026 | NT$489.7 million | +64.1% | +5.2% |
| Jul 2026 | NT$465.7 million | +17.2% | +3.3% |
| Jun 2026 | NT$450.9 million | +45.9% | +1.4% |
| May 2026 | NT$444.8 million | +22.8% | +19.8% |
| Apr 2026 | NT$371.3 million | -7.9% | -21.6% |
| Mar 2026 | NT$473.8 million | +32.4% | +25.1% |
| Feb 2026 | NT$378.6 million | +11.6% | +0.6% |
| Jan 2026 | NT$376.4 million | +49.8% | +11.7% |
| Dec 2025 | NT$337 million | +37.1% | -16.0% |
| Nov 2025 | NT$401.4 million | +46.3% | +21.6% |
| Oct 2025 | NT$330 million | -15.2% | -23.5% |
| Sep 2025 | NT$431.1 million | +39.1% | +44.4% |
| Aug 2025 | NT$298.5 million | -23.7% | -24.9% |
| Jul 2025 | NT$397.3 million | +19.7% | +28.6% |
| Jun 2025 | NT$308.9 million | -10.4% | -14.7% |
| May 2025 | NT$362.3 million | +22.1% | -10.1% |
| Apr 2025 | NT$403 million | +49.9% | +12.6% |
| Mar 2025 | NT$357.9 million | +42.5% | +5.6% |
| Feb 2025 | NT$339.1 million | +3.6% | +34.9% |
| Jan 2025 | NT$251.4 million | +6.4% | +2.2% |
| Dec 2024 | NT$245.9 million | -4.7% | -10.4% |
| Nov 2024 | NT$274.4 million | +33.0% | -29.5% |
| Oct 2024 | NT$389.3 million | +78.5% | +25.6% |
Jan–Oct 2026 cumulative: NT$4.47 billion (+28.6% YoY)
Other Biotech & Medical companies
Compare with peers: VISCO vs PEC / VISCO vs Lotus Pharm / VISCO vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
主因客戶需求成長,使營收較去年同期增加逾50%。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16